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Abstract 
Prion diseases, also known as transmissible spongiform encephalopathies (TSEs), are a 
group of debilitating neurodegenerative disorders that affect both humans and animals.  
They can be spread by horizontal transmission as seen in chronic wasting disease in 
deer and elk population.  In addition, transmission to humans has also been documented 
which includes bovine spongiform encephalopathy in cattle to variant Creutzfeldt-Jakob 
disease in humans due to consumption of contaminated meat.  The most probable 
natural route of transmission is by oral consumption of infectious material.  Even 
though this mode of transmission has been known for a long time it is still unclear how 
the infectious material distributes in vivo shortly after ingestion and what is the 
metabolic stability in gastro-intestinal tissues.  In this line, our hypothesis is that 
infectious prions resist gastro-intestinal digestion and directly cross the intestinal barrier 
after per-oral administration, distributing in blood and various organs.  In order to test 
this hypothesis, we characterized the metabolic profile of prions in gastro-intestinal tract 
tissues by in vitro experiments and determined the initial distribution of infectious 
material within hours of ingestion in vivo.  Our results showed the radiolabeled 125I-
PrPSc undergoes limited metabolic degradation -mostly in duodenum, jejunum  and  
ileum  tissue homogenates- as compared to stomach and colon homogenates where little 
degradation is observed.  We have also separately shown that within two hours of oral 
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ingestion of prions in mice self propagating prions are detected in blood, brain and 
various tissues. 
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Introduction 
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Prion diseases also known as transmissible spongiform encephalopathies 
(TSE’s) are a group of infectious, debilitating and fatal neurodegenerative diseases 
affecting both animals and humans (Prusiner, 1998).  Currently, there is no cure for 
these diseases and positive diagnosis is made after death by brain autopsy.  In humans 
one in a million cases per year globally are reported and can be inherited due to 
mutation in prion protein gene (<5%), sporadic without any known etiology (>95%), or 
acquired (<1%).  The latter comprises both human to human (iatrogenic) or animal to 
human (variant CJD) transmissions.  Although rare,  these diseases  remain intriguing 
due to the unique nature of infectious agents composed largely of misfolded proteins 
known as prions (Prusiner et al., 1983).  Prions were defined more than three decades 
ago by Dr. Stanley Prusiner as small proteinaceous infectious particles that resist 
inactivation by most procedures that modify nucleic acids (Prusiner, 1982).  In contrast 
to other infectious agents, like bacteria and viruses, prions resist inactivation by many 
conventional chemical treatments, ultraviolet radiation, heat, and nucleases (Gajdusek  
et al., 1977; Prusiner, 1982).  The infectious prion protein (PrPSc) forms as the result of 
a post-translational process that modifies the conformation of the endogenous cellular 
PrP (PrPC) into PrPSc (Borchelt et al., 1990; Caughey & Raymond, 1991).  As a result of 
the misfolding process, PrPC that is composed mainly of alpha helices undergoes a 
conformational change to intermolecular beta sheet as reported in PrPSc (Pan et al., 
1993).  In various prion diseases the clinical characteristics differ but they all share a 
common neuropathology which includes prion protein aggregate deposition, dendritic 
and synaptic loss, extensive spongiform brain degeneration, atypical inflammation and 
widespread neuronal death (Figure 1)(Budka, 2003; Soto & Satani, 2011) .  
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Figure 1. Multiple neurodegenerative pathways are involved in prion diseases. 
Brain abnormalities include PrP
Sc
 deposition, synaptic and dendrite loss, 
spongiform degeneration, brain inflammation and neuronal death.  Prion 
deposition was determined by IHC staining with anti-PrP antibodies.  The prion 
infected animal brain (upper) and normal uninfected (lower) is shown 
Reproduced, with permission, (Soto & Satani, 2011) (Copyright National 
Academy of Sciences, USA). 
Permission and license granted to use figure and legend in thesis from Elsevier 
and National Academy of Sciences. 
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1. Transmission of prion diseases in animals and humans 
Some prion diseases that are known to spread by oral transmission in animals 
include scrapie in sheep and goat, chronic wasting disease (CWD) in deer and elk, 
bovine spongiform encephalopathy (BSE) in cattle, Kuru and variant Creutzfeldt-Jakob 
disease (vCJD) in humans (Brown, 2009). 
1.1 Animal Prion Diseases 
1.1.1 Scrapie 
Scrapie is the most studied TSE and its history goes back to 1700’s where it was 
first reported in England by M’Gowan in 1710 (Plummer, 1946).  This is a natural prion 
disease that can affect sheep and goat.  Initial transmission studies done by Dammann  
in 1869, M’Fadyean in 1918 and Bertrand et al., in 1937 were negative as these studies 
failed to follow the long incubation period required for disease progression (Plummer, 
1946).  However, once the long incubation period for this disease was recognized it was 
shown to be transmissible to goats (Cuille and Chelle, 1936) and later by accidental 
transmission to sheep herd by administration of a contaminated vaccine (Gordon, 1946). 
Histopathologically, Brownlee in 1940 reported the presence of large vacuoles in 
medulla and spinal cord of all animals affected with scrapie (Plummer, 1946).  
Hallmark clinical symptoms of scrapie included intensive skin irritation caused by 
itching, rubbing and scratching which resulted in the animal rubbing itself against the 
posts, followed by motor and sensory impairments leading to ataxia or complete 
paralysis (Plummer, 1946).  Environmental transmission was observed when unaffected 
sheep acquired the disease when grazed on pastures in previous contact with affected 
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animals (Plummer, 1946).  To date, oral exposure of the contaminated agent has been 
shown to be a major  route of entry for the infectious agent ( Andreoletti et al., 2000; 
Greenlee & Greenlee, 2015; Gough K.C. 2010 and  van Keulen et.al., 2002).  However, 
recently, classical scrapie has been shown to be transmitted to cynomolgus macaque 
(which is the preferred animal model to study human prion diseases) after long 
incubation periods (Comoy et al., 2015). 
1.1.2 Chronic Wasting Disease (CWD) 
Chronic wasting disease is a horizontally transmissible disease that has been 
reported to affect free ranging and captive deer, elk and moose populations in the 
United States, Canada and South Korea (Sohn et al., 2002).  After its first appearance in 
Colorado in the 1960’s, the disease quickly expanded (Kuznetsova, et al., 2014).  
Clinical symptoms include excessive thirst, behavioral alterations and progressive 
weight loss followed by death in 2 weeks to 8 months (Williams, 1980).  Although it is 
not conclusively known how CWD is transmitted in the natural environment, it has been 
shown that prion contaminated soil and plants can spread the infectious agent and cause 
disease (Johnson et al., 2007; Pritzkow et al., 2015).  CWD prions have been detected 
saliva, urine and feces of CWD infected deer by either in vitro PrPSc detection assays or 
in vivo infectivity bioassays (Haley et al., 2011; Henderson et al., 2015).  Oral exposure 
to contaminated material has been implicated as the most probable route for disease 
transmission (Denkers, Telling, & Hoover, 2011). 
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1.1.3 Bovine Spongiform encephalopathy (BSE) 
BSE, also known as “mad cow disease”, was first reported in Great Britain in 
the mid-1980’s where more than 1000 cases of neurological disorder in cows were 
reported within a period of two years (Hope et al., 1988).  It was suspected that the most 
likely source of transmission in cattle was due to food-borne transmission (Parodi et al. 
1990).  This was later confirmed in 1996  when more than 160,000 cases of BSE were 
reported in the Great Britain with most likely source of origin being contamination of 
cattle’s supplementary feed with meat and bone meal (MBM) from scrapie infected 
animals (Wilesmith et al. 1991; Anderson et al., 1996).  Since then, considerable 
measures were taken that resulted in significant reduction in BSE cases in cattle (Budka 
et al., 2008).  BSE may manifest clinically as changes in behavior that may include 
aggressiveness and motor impairment accompanied by weight loss.  Even though BSE 
was suspected to arise from scrapie-contaminated MBM fed to cattle, the infectious 
agent responsible was found to be biochemically different than the one involved in 
scrapie (Stack et al., 2002).  Although there was a steady decline in BSE cases, a new 
variant form of Creutzfeldt-Jakob diseases was identified in 1996 that raised suspicions 
of disease acquired by consumption of meat that was contaminated with BSE infected 
cow (Will et al. 1996).  Later transmission studies along with immunochemical analysis 
were able to confirm that the same agent involved in BSE in cows is also responsible 
for vCJD in humans (Collinge et al. 1996; Bruce et al. 1997; Hill et al. 1997; 
Weissmann & Aguzzi, 1997) 
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1.2 Human Prion Diseases 
1.2.1 Kuru 
Kuru was one of the first human prion diseases that were shown to be 
transmissible.  This disease was first described by Gadjusek and Gibbs in 1959 in the 
fore people of Papua, New Guinea (Gajdusek & Zigas, 1959).  The disease was 
characterized by cerebellar ataxia accompanied by tremor, choreiform and athetoid 
movements (Gajdusek & Zigas, 1959; Liberski P, 2012).  It was believed to be spread 
due to a cannibalistic ritual that involved consumption of infected brains from the 
deceased.  This was one of the first piece of evidence for oral transmission of prion 
diseases in humans.  Later, in a breakthrough study, three chimpanzees intra-cerebrally 
challenged with brain extracts of kuru infected patients developed a disease similar to 
the one seen in humans (Gadjusek, 1966).  
1.2.2 Variant Creutzfeldt-Jakob disease (vCJD) 
As mentioned previously, a novel form of human prion disease was reported in 
the mid- nineties coinciding with the time BSE was epidemic in Great Britain (Will et 
al.; 1996; Collinge J and Rossor, 1996).  Variant CJD, also known as the human 
equivalent of BSE, is of public health concern as its mode of transmission is food-
borne.  Consumption of BSE-infected cattle meat was the most likely route for 
transmission into humans (Ward et al., 2006) The incidence of vCJD has continued to 
decline since the outbreak in mid-nineties due to the BSE related feed control policy 
that was adopted by the United Kingdom (Will, 2003) but of concern now is the 
secondary spread of the disease by iatrogenic transmission (blood transfusions, 
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contaminated surgical instruments) as the incubation period for CJD can span for 
decades.  Clinical features involve sensory and psychiatric symptoms followed by 
ataxia, cognitive impairment and involuntary movements (Zeidler et al., 1997). 
Neuropathologically, along with the rest of prion disease pathology, PrPSc positive florid 
amyloid plaques are present (Will, 2003).  As vCJD is spread by consumption of 
contaminated BSE infected meat, there is also considerable peripheral deposition of 
PrPSc as found in skeletal muscle (Peden et al., 2006) and the lymphoreticular system 
(Hilton et al., 2004).  
1.2 Pathogenesis of prions after oral ingestion 
Even though oral transmission for prion diseases has been known for a long 
time, as shown by naturally or by deliberate inoculation of infectious agents (Maignien, 
et. al., 1999) surprisingly very little work has been done to determine the immediate 
fate of the infectious agent after ingestion.  Previous studies have shown the localization 
of infectious particles in Peyers’ patches of ileum and mesenteric lymph nodes (Aguzzi 
2003; Bergstrom et. al 2006) followed by retrograde transport to the brain via peripheral 
nerves.  Presence of PrPSc in spleen and gut-associated lymphoid tissues (Andreoletti et 
al., 2000) suggests that even after metabolic processing of PrPSc in the gastro-intestinal 
track the infectious agent is not degraded and is transported across the intestinal barrier. 
Many studies have been done showing trans-cellular transport of prions across the 
intestinal epithelial barrier from the apical (mucosal) side to basolateral (serosal) side in 
cell monolayers (Heppner et al., 2001; Mishra et al., 2004).  Caco-2 cellular models for 
intestinal barrier have shown that PrPSc can cross the barrier by endocytosis upon 
interaction with the laminin receptor (Morel et al., 2005).  On the other hand, it has also 
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been shown that M cells mediate transcytosis of prions across epithelial cell monolayers 
(Heppner et al., 2001).  In another study, Mishra et al. have shown that a prion-ferritin 
complex is trans-cytosed in Caco-2 cell monolayers (Mishra et al., 2004).  These studies 
point out that after crossing the basolateral side PrPSc is immediately absorbed by 
dendritic cells circulating in blood.  Studies using infectivity and histological techniques 
have shown that the circulatory system does not play a major role in PrPSc transport and 
the infectious agent is directly taken up by the enteric nervous system (Maignien et al., 
1999; Kimberlin & Walker, 1989).  Also, rapid appearance of infectious agent in sub-
mucosal lymphatics and not in Peyer’s patches of intestine has been shown in isolated 
gut loops inoculated with prions (Jeffrey et al., 2006).  These results suggest that most 
likely once ingested prion protein can be transported by both peripheral nerves and/or 
blood.  However, most of these studies used methods and techniques that rely on 
detection of prions after peripheral replication and not the original material 
administered.  It is important to note that neither conventional histology nor infectivity 
studies have the sensitivity to detect the immediate transport of PrPSc within minutes or 
hours after oral exposure.  One breakthrough technique for detection of prions that has 
led to substantial advances in the past decade is the Protein Misfolding Cyclic 
Amplification technology (PMCA).  PMCA technology effectively enables prion 
replication even from a single oligomeric particle of PrPSc  (Saborio, Permanne, & Soto; 
2001; Saá et al., 2006).  Unlike conventional techniques, the great sensitivity achieved 
from this technique to amplify otherwise undetectable amounts of PrPSc has allowed for 
detection of prions in various bodily fluids at both pre-symptomatic and post-
symptomatic stages of the disease (Saa, P., 2006; Chen, Morales, Barria, & Soto, 2010; 
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Moda et al., 2014).  In addition, by using this technique it has been recently reported 
that inoculated prions can be detected at short times after intraperitoneal administration 
in experimental hamsters (Chen et al., 2014).  The schematics involved in the PMCA 
technique are shown in Figure 2 and expanded in the Methods section.  A detailed 
study to determine the distribution and metabolism of PrPSc immediately after oral 
ingestion can provide key evidence to determine the bioavailability of prions and 
development of therapeutic strategies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
 
Figure 2: Schematic diagram for protein misfolding cyclic amplification. PMCA is based on 
the assumption that prion replication occurs by a seeding/nucleation model (Caughey, 2003), 
in which PrP
Sc
 seeds bind and misfold PrP
C
 by incorporating the protein into the polymer. In 
PMCA, PrP
Sc
 and PrP
C
 are mixed and incubated, allowing the misfolding of PrP
C
, which 
permits the incorporation and growth of PrP
Sc
 aggregates. After incubation, samples are 
submitted to sonication in order to fragment PrP
Sc
polymers, thereby generating new free ends 
suitable for continued prion replication. This process is cyclically repeated in order to produce 
an exponential amplification of PrP
C
 conversion (Morales, et al., 2012) (figure with legend 
reproduced with permission from  Nature Publishing Group). 
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Hypothesis 
 
Our hypothesis is that infectious prions resist gastrointestinal metabolism and directly 
cross the intestinal barrier after per oral administration, distributing in blood and various 
organs.  In order to test this hypothesis, we will address following two aims: 
characterization of the metabolic profile of prions in gastrointestinal tract tissues by in 
vitro experiments and determination of the initial distribution of infectious material 
within hours of ingestion in vivo. 
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Materials and Methods 
Ethics statement 
All animal experiments were approved by and conducted in strict accordance 
with guidelines of the Animal Care and Use Committee of the University of Texas 
Health Science Center in Houston and complied with the recommendations in the Guide 
for the Care and Use of Laboratory Animals of the National Institutes of Health. 
2.1 Production of prion proteins in host animals: 
2.1.1. Animal infection with Rocky Mountain Laboratories (RML) scrapie  prions 
The Inoculum for the infection study was prepared as follows; 
Two mouse brains infected with RML prion strain were homogenized in 10mL 
Dounce homogenizer.  A 10% homogenate was prepared in 1x PBS with protease 
inhibitor.  The homogenate was spun down at 2000xg for 5 minutes. The supernatant 
was collected for inoculation in mice and debris was discarded.   
2.1.1. Animal inoculation with RML prions 
Twenty five female 129S2 mice at the age of 3-4weeks were purchased from 
Harlan laboratories (Houston, Texas).  Mice were divided in groups of five in each cage 
and ears were punched for identification.  They were housed in light and temperature 
controlled mouse prion room with 12 hours of light and dark cycles and free access to 
water and food.  Each mouse was inoculated intraperitonealy with 100 µL of RML 
inoculum. After inoculation, mice were inspected daily for signs of prion disease.  At 
seven months, the symptoms for early clinical stage of scrapie including piloerection, 
hunched posture and ungroomed appearance, were observed.  At the terminal stages of 
disease which were defined by clinical signs of unsteady gate, ataxia, and limb 
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paralysis, mice showed 20% of body weight loss or complete paralyses were sacrificed.  
The brain was harvested from each mouse and frozen at -80°C for purification 
experiments. 
2.2 Purification of PrPSc 
Purification of PrPSc from the infected brain was performed as described 
previously (Hetz et al., 2003) with modifications.  A 10% brain homogenate (w/v) was 
prepared in 1xPBS with 20% Sarkosyl to precipitate prion proteins.  The mixture was 
thoroughly sonicated using a probe sonicator (Bandelin Sonoplus) at power of 45% 
until it became clear. Then, the mixture was then centrifuged for 15 min at 5311 x g at 
4°C (Beckman Coulter Allegra 25R). To the supernatant, 1/3 volume of 1X 
PBS/0.1%SB3-14 was added and ultra-centrifuged using T 70.1 rotor at 198,000 x g for 
2h at 20°C (Beckman Coulter Optima XE-90 Ultracentrifuge).  The resulting pellet was 
reconstituted with 1 ml of 1xPBS/10%NaCl/0/1%SB3-14, and sonicated until clear 
solution was obtained. One mL of the mixture  was layered over 3 mL of 20% sucrose 
cushion made in 1x PBS/10% NaCl/0.1% SB3-14.  This material was then ultra-
centrifuged at 257,000 x g for 3h at 4°C using T 70.1 rotor.  The pellet was dissolved in 
1mL of 1xPBS/0.1%SB3-14 and extensively sonicated until the solution became clear. 
Then Proteinase K (PK) (Sigma-Aldrich) was added at the final concentration of 
100µg/mL and the mixture incubated at 37°C for 2 h (Eppendorf Thermomixer R).  The 
PK digestion process was stopped by adding 1mM of Pefabloc SC (Roche).  Next, this 
material was sonicated and centrifugation with sucrose gradient for 1.5 h repeated. The 
final pellet was re-suspended in 300µL of sodium phosphate buffer (pH 7.4).  
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The preparation was labeled as purified PrPSc.  Western blot and silver staining was 
performed with the purified PrPSc to confirm the purity of the material.  The 
concentration of PrPSc was determined by micro BCA protein assay kit (Pierce). 
2.3 Western blot of Purified PrPSc  
Ten µL of purified PrPSc was dissolved in 1x sample buffer with 1mM DTT 
(Life Technology Inc. LDS sample buffer), the mixture heated for 10 min at 100°C, 
briefly spun down and loaded on 12% NuPage Bis-Tris gel (Life Technologies Inc). 
Also, 3µL of protein ladder (Fisher BioReagents™ EZ-Run™ Pre-Stained Rec Protein 
ladder) was loaded.  The gel was run for 20 min at 70V and 1.5 h at 135V with 1x MES 
SDS running buffer (NuPage).  After SDS-PAGE, the proteins were transferred at 
constant current of 0.8A at 4°C to a nitrocellulose membrane (GE Healthcare 
Amersham™ Protran™ premium 0.45µm NC) for 1 h.  The membrane was blocked for 
to prevent unspecific protein binding by treating with 2% milk in PBST 0.05% for 1 h 
at room temperature.  Following blocking, the membrane was incubated with 6D11 
monoclonal antibody (Covance) diluted at 1:2500 at 4°C overnight on shaker.  Next 
day, the membrane was washed for 10 min three times in washing buffer at room 
temperature.  Thereafter, the membrane was placed in washing buffer containing anti-
mouse IgG Secondary antibody (Sigma Aldrich anti-mouse IgG) diluted at 1:3000, and 
incubated at room temperature for 1hr with gentle shaking followed by three 10 min 
washes with PBST 0.05%.  The membrane was developed using ECL prime kit (GE 
Healthcare Amersham ECL prime western blotting).  
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2.4 Silver Staining of PrPSc   
Following gel electrophoresis, silver staining was carried out using silver 
staining kit (Invitrogen SilverXpress silver staining kit).  All steps were performed 
according to the instruction from the manufacturer. 
2.5 Radiolabeling of purified PrPSc  
Radiolabeling of purified PrPSc was performed  by  chloramine-T method with 
[125I]Na (Perkin-Elmer), as described in previous reports (Gitlin et al., 1958 ; Urayama 
et al,. 2004).  Purified PrPSc (10 µg) was mixed with [125I] Na (2 mCi) in 250 mM 
chloride-free sodium phosphate buffer (pH 7.4), and the protein labeling was initiated 
by adding chloramine-T (10 µg/reaction) into the mixture.  After 1 min, the reaction 
was terminated by adding sodium metabisulfite (100 µg/ reaction).  Each labeled agent 
was purified by Sephadex G-10 chromatography to remove free iodine. The labeled 
PrPSc was diluted with phosphate buffered saline and further centrifuged in albumin pre-
coated Microcon filtration tube (Mw cutoff: 10 kDa) at 12,000 rpm for 30 min to further 
remove free iodine from the G-10 eluate.  Labeled PrPSc was extensively washed by this 
procedure.  Radioactivity was measured after each wash (Cobra II gamma counter, 
Packard).  The radioactively labeled PrPSc preparations we used had > 90% 
precipitation with trichloroacetic acid (TCA) (Sigma).  
2.6 Preparation of tissue homogenates for in vitro metabolism study 
Female 129S2 mice at 8-10 weeks of age were fasted for 16 h prior to being 
sacrificed for gastro-intestinal tissue collection.  Following tissues were obtained for 
homogenate preparation, stomach, duodenum, jejunum, ileum and colon.  Ten % (w/v) 
tissue homogenate in saline were freshly prepared on ice each time of experiment 
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(prepared in a Precellys 24 device).  Each homogenates was spun for 5 min at 3000 x g 
at 4°C (Beckman Coulter Allegra 25R).  The supernatant was saved for the study.   
2.7 Tissue metabolism of 125I-PrPSc 
Metabolic profiling of 125I-PrPSc was investigated by following procedure. 
Tissue homogenate (1mL) was incubated with 125I-PrPSc (3 x 105 cpm) for 1, 3 and 6h at 
37°C on a thermomixer (Eppendorf Thermomixer R) shaking at 600rpm.  Three 
hundred µL aliquot was sampled at designated time points, and the sample frozen in 
liquid nitrogen for HPLC analysis at later time.  Saline was also incubated with 125I-
PrPSc for control experiments. 
2.8 Size-exclusion HPLC experiments 
The stability of 125I-PrPSc in stomach, duodenum, jejunum, and ileum and colon 
homogenates was examined using HPLC with a size exclusion column. HPLC system 
used for this study consisted from Shimadzu UFLC system LC-20AB and the size 
exclusion column BioSep-SEC-S4000 (7.8 mm × 300 mm, Phenomenex, CA).  The 
mobile phase consisted of 25 mM sodium phosphate buffer (pH 7.4)  Tissue sample was 
centrifuged at 12,000 x g for 10 min (Eppendorf Centrifuge 5415D).  The supernatant 
(300µL) was separated and loaded onto HPLC column. Fractions were collected at 
1mL/min interval for first five min followed by 10-second intervals for 5-15 min at a 
flow rate of 1.0 mL/min, and the radioactivity in each fraction was detected using a 
gamma counter.  TCA precipitation of each fraction was also performed.  Molecular 
weight markers, including thyroglobulin (669kDa), aldolase (158kDa), conalbumin 
(75kDA), carbonic anhydrase (29kDa) and aptotinin (6.7kDa) (GE Healthcare Gel 
Filteration Calibration kit HMW) were employed to estimate the relationship between 
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the size and retention time  A single peak for each marker was confirmed and the peak 
time defined as the retention time.  In addition, the retention time of Iodine-125 was 
measured.  
2.9 Data analysis and statistical analysis 
The radioactivity normalized by % of injected amount in each eluate from size-
exclusion chromatography was plotted against retention time.  The areas under the 
curve (AUC) values were calculated from the fractions between 6.0 and 10.0 min, 
which represents intact 125I-PrPSc.  The radioactivity below 3 times of the background 
level (70 cpm) was excluded from the analysis which was seen after 11.0 min. 
TCA precipitation was performed to estimate the levels of intact 125I-PrPSc.  
For TCA precipitation, following was done: 
In each HPLC fraction 100µL of 1% BSA (Sigma Aldrich) prepared in DI water 
was added followed by ice cold 500µL of 30% TCA (Sigma Aldrich) prepared in DI 
water. This mixture was then centrifuged for 15 min at 4000 x g at 4˚C. The supernatant 
and pellet was separated and the radioactivity in each was measured. 
The radioactivity in each pellet and supernatant and % of radiolabeled protein was 
calculated by the following formula: 
TCA%= cpm in pellet/ (cpm in pellet+cpm in supernatant)*100 
2.10 Statistics analysis 
Statistical comparison was performed by one-way ANOVA followed by 
Dunnet’s multiple comparison test against percent area under the curve (%AUC) from 
the pre incubated input 125I-PrPSc. 
19 
 
Methods and materials for distribution of  PrPSc in vivo after oral ingestion 
2.11 Inoculum preparation 
Two symptomatic (RML prion strain) infected mice were sacrificed by CO2 
inhalation and brains were harvested.  Ten percent homogenate (w/v) was prepared in 
PBS supplemented with a cocktail of protease inhibitor (Roche Diagnostics).  The 
homogenate was further processed as described previously (Morales et al., 2012).  The 
homogenate was briefly centrifuged at 800 x g for 1 min at 4°C (Beckman Coulter 
Allegra 25R).  The supernatant was collected and incubated with 20% sarkosyl 
(prepared in PBS) for 15 min at room temperature on rotator.  The resulting sample was 
then ultra-centrifuged using T70.1 rotor at 100,000 x g for 1 h at 4°C (Beckman Coulter 
Optima XE-90 Ultracentrifuge).  Supernatant was discarded and two volumes of 1x 
PBS + PI were added and ultra-centrifuged again at 100,000 x g for 30 min at 4°C.  The 
final pellet was re-suspended and sonicated in one volume of PBS + PI and frozen at -
20°C for Western blot analysis and animal inoculations. 
 
2.12 Oral inoculation of PrPSc in mice  
Three female mice 129S2 aged at 8-10 weeks were fasted for 16 h prior to 
inoculation.  Each animal was given 500 µL of inoculum and culled after two hours. 
Blood (heparinized, 12.5 mg/mL), brain, spleen, liver, colon, intestines and stomach 
were collected.  Extreme precaution was taken while tissue collection to prevent cross 
contamination.  Surgical instruments, decontaminated by immersion in 2N NaOH 
solution for 24hrs, were used for organ collection.  Each tissue had separate sets of 
surgical instruments.  The blood after ficol (GE Healthcare) was then separated into 
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plasma, buffy coat and red cells as suggested by the manufacturer (GE ficol paque).  
Each tissue sample was frozen in -80°C for PMCA experiments. 
2.13 Tissue homogenates preparation for PMCA 
Forty percent tissue homogenates were prepared as described above and treated 
with 20% sarkosyl prepared in PBS and ultra-centrifuged as explained in section 2.11. 
The final pellet was re-suspended in 100µL of PMCA substrate (mouse) prepared in 
conversion buffer as previously described (Morales et al., 2012) and later on in this 
section.   
2.14 Blood components processing 
The plasma and buffy coat collected (400µL) was mixed with equal volumes of 
PBS + PI and ultra-centrifuged at 100,000 x g and 4°C for 1h.  Two volumes PBS + PI 
were added to resulting pellets and ultra-centrifuged in the same conditions mentioned 
above for additional 30mins. Final pellets were re-suspended in PMCA substrate. 
2.15 Protein Misfolding Cyclic Amplification 
The PMCA protocol was carried out as reported previously (Morales et al., 
2012).  PMCA substrate (wild-type mouse brain homogenate) was prepared as 
described previously (Morales et al., 2012).  129S2 mice were sacrificed by CO2 
inhalation and brains were collected following perfusion with PBS + 5mM EDTA. 
Immediately after harvesting, the tissue was frozen in liquid nitrogen and stored in -
80°C.  PMCA substrate preparation was done as following:  10% brain homogenate 
(w/v) was prepared in conversion buffer (150mM NaCl, 1% Triton X-100 in 1X PBS) 
with PI.  Tissue pellets that were re-suspended in PMCA substrate were submitted to 
PMCA (Morales et al., 2012).  The PMCA was carried out in an automatic horn 
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sonicator (Qsonica).  Samples (in individually capped 0.2 mL PCR tubes) were placed 
in PMCA tube holder placed on an automatic horn sonicator (Qsonica) filled with water 
at 37°C and submitted to 240 PMCA cycles for first round followed by two rounds of 
96 cycles.  Each cycles consisted of 29 min and 40 sec of incubation in water bath at 
37˚C followed by 20 second of sonication at Amplitude 30 and power between 260-
300W.  At the end of each round serial dilutions were made by diluting 10µL of the 
resulting material into 90µL of fresh PMCA substrate.  These new mixtures were 
subjected to additional PMCA rounds to increase amplification efficiency.  After each 
round, 19 µL of sample were saved for Western blot analysis.  
2.16 Western blotting of PMCA amplified material 
Samples saved from each PMCA round were treated with 50µg/mL PK and 
incubated for 1 h at 37°C with shaking. PK reaction was stopped by addition of sample 
buffer supplemented with 1mM DTT and heated for 10 minutes at 100°C.  Western 
blots were then done on each sample as described above in 2.3. 
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CHAPTER 3  
Results 
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3.1 Purification and radiolabeling of PrPSc from infected brain, and 
characterization  of size-exclusion HPLC chromatography 
 Figure 3 shows immunoreactivity and protein purity of purified PrPSc of RML 
prion strain obtained through experimental procedure (Section 2.2).  The presence of 
PrPSc in SDS-PAGE and subsequent western blotting was confirmed by silver staining 
in gels and specific immunoreactivity probed by 6D11 monoclonal antibody.  PrPSc 
bands were ranged within the molecular weights between 27kDa and 30kDa as reported 
previously (Bendheim et al., 2015).  After PK digestion the electrophoretic mobility of 
PrPSc (Figure 3) shows a majority of monoglycosylated isoform of prion protein and 
size of about 21kDa for the unglycosylated band (Morales et al., 2007). 
The purity was confirmed by silver staining in which protein derived bands other than 
PrPSc were not observed.  Silver staining and western blotting of PrPSc were conducted 
each time when purification of PrPSc from infected brain was performed, and results 
were reproducible.   
Radiolabeling of PrPSc was performed with these preparations.  Tricholoacetic acid 
assay showed >90 percent of purified PrPSc protein being successfully labeled with 125I. 
The size distribution of 125
exclusion radio-HPLC chromatography
for TCA precipitation to estimate intactness of 
times in size-exclusion column were
(Table 1), For markers the
(669kDa), 9.45 minutes for 
10.8 minutes for carbonic anhydrase (29kDa) and 12.0 minutes for 
Also, the retention time for i
 
I-PrPSc based on molecular weight was analyzed by 
 (Figure 4A).  The HPLC eluate was 
125I-PrPSc.  In addition, the retention 
 characterized with high molecular weight markers
 retention times were; 7.35 minutes for thyroglobulin 
aldolase (158kDa), 10.0 minutes for conalbumin (75kDa), 
aprotinin (6.5kDa).  
odine-125 was 12.3 minutes (Fig 4B).  
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125I-PrPSc (1x105 cpm) (now will be referred to as input 125I-PrPSc) was injected onto the 
column and fractions were collected at the flowrate of 1mL/min from 1-5 min at 1 min 
interval and from 5-13 min at 10 sec intervals.  
The radio chromatogram of input 125I-PrPSc (1x105 cpm) is shown (Figure 4A).  125I-
PrPSc was injected onto the column and fractions were collected at the flowrate of 
1mL/min from 1-5 min at 1 min interval and from 5-13 min at 10 secs intervals.  On x-
axis is time in min and right y-axis is raw cpm (blue) and TCA normalized cpm (red) 
(Figure 4A).  On right y-axis is percent of injected dose/mL (%ID/mL) plotted (Figure 
4A). The chromatogram of 125I-PrPSc spans between 6.0 -10.0 min showing various 
sizes ranging from 669 to 29 kDa (Figure 4A). Separately, iodine-125 was 
characterized in the column showing a retention time at 12.3min (Figure 4B).  
 
 
 
 
 
 A. 
B. 
Figure 4. Radio-HPLC chromatogram of 
markers is shown. The area under the curve was analyzed for 6.0 
minutes as shown by red 
Retention time of iodine
 
 125I-PrPSc with molecular weight 
-10.0 
line under x-axis (A) 
-125 was 12.3 minutes (B) 
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Protein Molecular Weight (Da) Retention time (minutes) 
Thyroglobulin 669,000 7.35 
Aldolase 158,000 9.45 
Conalbumin 75,000 10.00 
Carbonic anhydrase 29,000 10.80 
Aprotinin 6,500 12.00 
 
 
3.2 Characterization of metabolic pattern of radioactively-labeled, PrPSc by 
trichloroacetic acid precipitation assay (TCA) and high-performance liquid  
chromatography (HPLC ) in vitro 
Next, freshly prepared tissue homogenates (stomach, duodenum, jejunum, 
ileum, and colon) were incubated with 125I-PrPSc (3x105 cpm) for 1, 3 and 6 h and 
analyzed by radio-HPLC chromatography (Figure 5).  The %ID/mL of tissues was 
plotted with input 125I-PrPSc (Figure 5).  As a processing control, 125I-PrPSc was also 
incubated with saline.  The radio-chromatogram of saline shows minimal changes in 
125I-PrPSc after 1hr (Figure 5A).  The radio chromatogram of stomach, colon, and saline 
control (Figure 5B, 5F and 5A) shows the major peaks between 6.0-10.0 min which 
was similar to the input 125I-PrPSc.  In contrast, the duodenum (Figure 5C) , jejunum 
(Figure 5D) and Ileum ( Figure 5E) showed decrease in intact protein of 125I-PrPSc 
compared to input 125I-PrPSc, indicating that the amount of intact125I-PrPSc was reduced 
in duodenum, jejunum and ileum tissue 1h after incubation.  In addition to 1 h, for each 
Table 1. High molecular weight markers  retention times in Phenomenex Bio sep sec 
s4000 size exclusion column  
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tissue homogenate samples collected at 3 h and 6 h were also injected in HPLC column 
and chromatograms were analyzed.  Results were similar to the 1hr time point (Figures 
6 and 7). 
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Figure 5. Radio HPLC-Chromatogram of tissue homogenates incubated with 
125
I- 
PrP
Sc 
at 1hr. Saline only (A) , Stomach (B), Duodenum (C) , Jejunum (D), Ileum(E) 
and Colon(F) %Injected dose per mL (%ID/mL) of input125I- PrPSc (red)  and 
%Injected dose per mL (%ID/mL)of tissue homogenates (green). The red line on x-
axis of each graph marks the time (6.0-10.0min) measured for calculating total area 
under the curve. 
A. B. 
C. D. 
E. F. 
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Figure 6. Radio-HPLC Chromatogram of tissue homogenates incubated with 
125
I- 
PrP
Sc 
at 3hr. Saline only (A), Stomach (B), Duodenum (C), Jejunum (D), Ileum (E) 
and Colon (F) %Injected dose per mL (%ID/mL) of input 125I-PrPSc (red)  and 
%Injected dose per mL (%ID/mL)of tissue homogenates (blue). The red line on x-
axis of each graph marks the time (6.0-10.0min) measured for calculating total area 
under the curve 
A. B. 
C. D. 
E. F. 
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Figure 7. Radio-HPLC Chromatogram of tissue homogenates incubated with 
125
I- PrP
Sc 
at 6hr. 
Saline only (A), Stomach (B), Duodenum (C), Jejunum (D), Ileum (E) and Colon (F)  
%Injected dose per mL (%ID/mL) of input 125I-PrPSc (red) and %Injected dose per mL (%ID/mL) 
 of tissue homogenates (purple). The red line on x-axis of each graph marks the time (6.0-10.0 
min) measured for calculating total area under the curve 
A. B. 
C. D. 
E. F. 
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Time in Hours Stomach Duodenum Jejunum Ileum Colon Saline only 
1 70.2 ± 16.2 36.3 ± 7.2 37.4 ± 7.1 56.2 ± 9.2 64.4 ± 16.5 60.4 ± 11.7 
3 64.3 ± 11.2 29.3 ± 7.2 35.2 ± 8.1 42.3 ± 5.7 56.4 ± 19.3 64.0 ± 9.5 
6 79.0 ± 14.2 28.5 ± 9.1 31.0 ± 11.2 42.1 ± 7.7 56.3 ± 22.1 67.5 ± 14.3 
 
 
The in vitro metabolite study to measure intactness of PrPSc in gastro-intestinal tissue 
homogenates at various time points was repeated by performing three separate 
experiments.  The mean and SEM of % area under the curve (AUC) (measured between 
6.0-10.0 min) for all tissues at different time points is shown (Table 2).  
In table 2 the mean of %AUC (6.0-10min) along with its respective SEM is listed for 
each tissue. As seen by table 2 the change is metabolic profile for duodenum, jejunum 
and ileum is time-dependent and compared to input
125
I-PrP
Sc
.  The amount of reduction 
seen in graph duodenum, jejunum and ileum homogenates (Figure 8) are less than 50% 
as compared to the input 125I-PrPSc. 
 
 
 
 
 
 
Mean ± SEM (n=3) are reported 
Table 2: %AUC in tissues is based on the AUC value compared to the input 125I-PrPSc as 100 ± 20.7% 
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Figure 8.  Figure 8.  Gastrointestinal (GI) metabolite profile of 125I-PrPSc after 
incubation with 10% mouse tissue homogenates. (A) The metabolic profile of 
stomach, duodenum and jejunum. (B) The metabolic profile of ileum, colon and saline 
only control. Each time point represents the mean value and standard error of the 
mean. All measurements were done in triplicates.  Comparison of total area under the 
curve (6.0 – 10 min) of tissue homogenates incubated with 125I- PrPSc all time points 
against input material (125I- PrPSc) as 100% ± 20.7 
Statistical comparison was performed using one-way ANOVA followed by Dunnet’s 
multiple comparison tests 
*p <0.05, **p<0.01 
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Summary  
 
In-vitro metabolic profile of prions in gastro-intestinal tissues 
Detailed analysis of metabolic profile of 125I-PrPSc in gastro-intestinal tissues 
showed the amount of reduction in intact 125I-PrPSc with time. The significant reduction 
is seen in the duodenum, jejunum and ileum, which is mediated through endogenous 
protease activity. 
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3.3 Detection of self-propagating prions in blood and tissues after per-oral 
inoculation using the protein misfolding cyclic amplification (PMCA) technology 
 As a preliminary approach to bio-distribution studies, we designed and 
performed experiments aimed to quantitatively detect self-replicating prions in blood 
and tissues of mice orally challenged with misfolded PrP.  To study the immediate 
distribution of PrPSc in vivo, first we prepared a homogeneous inoculum suitable for our 
purpose (i.e. free from tissue debris).  The material to inject in mice was prepared by 
mixing one volume of 10% BH and one volume of a 20% sarkosyl solution in order to 
disrupt membranes and isolate protein aggregates from unspecific bound molecules.  
After 15 min incubation at RT gently shaking, samples were ultra-centrifuged.  
Resulting pellets were washed and finally re-suspended in saline buffer using extensive 
sonication (see chapter 2).  Western blots of 10% RML brain homogenate before and 
after treatment are shown in Figure 9. As seen in the figure, this treatment resulted in a 
minimal loss of PrPSc, data consistent with previously published results (Morales et al., 
2008).  Next, this inoculum was subjected to PMCA (see chapter 2 methods and 
materials) to set in vitro amplification conditions for this specific inoculum (Figure 10). 
Three PMCA rounds were done 48 h each round (see Chapter 2 for details).  The initial 
samples, labeled as frozen (not submitted to PMCA) are shown (Figure 10A).  As 
expected, they do not show positive signal in the Western blot due to their high dilution. 
After first round, 10-5 dilution of inoculum was detected (Figure 10B).  Following 
PMCA rounds revealed presence of misfolded prions in 10-10 brain dilution (Figure 
10C and Figure 10D).  Also two negative controls containing 10% normal mouse brain 
homogenate only were added to the PMCA reaction to control for inter
contamination.  As expected, results were negative confirming true PrP
Bioassays were performed by injecting 500µL of this inoculum per orally in three wild 
type mice to study short-term distribution in various tissues.
 
 
 Figure 9.  Western blot of 10% PrP
dilutions (A). 
homogenate dilutions after sarkosyl treatment 
were treated with
First lane on both A and B is 10% normal mouse brain 
homogenate without PK treatment for reference.
A. 
B. 
 
Sc
 detection. 
 
 
Sc
 (RML) brain homogenate 
Western blot of 10% PrPSc (RML) brain 
(B). All samples 
 PK 50µg/mL, 1 h at 37°C, shaking at 600rpm.
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Prior to inoculation, mice were fasted for 16h with free access to water in order 
the gastro-intestinal tract from fecal material. 
A. 
B. 
C. 
D. 
Figure 10. Western blot of “sarkosyl cleared” inoculum after PMCA.
brain substrate (A) not submitted to the PMCA reaction (frozen). PMCA amplification after first, 
second and third rounds (B - D).
sample in that lane (B). 
 
 
 
 Two hours after per oral administration 
 Dilutions of inoculum in normal 
 Labelled in red is the negative control on each g
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of prion containing material, the three mice were culled and blood, brain, spleen, liver, 
colon, intestines and stomach were collected respectively.  For each tissue, either 10% 
(stomach, intestines, colon, liver, spleen, brain) or 40% homogenates (stomach, 
intestines, colon, liver, spleen, brain) (w/v) were prepared in PBS supplemented with PI 
and subjected to PMCA (see Chapter 2 for details).  Before PMCA, Western blots were 
performed on 10% tissue homogenates (w/v) in order to assess for direct visualization 
of PrPSc by this method.  As expected, none of the tissues analyzed showed positive 
signal for PrPSc, indicating that the concentration in each tissue was below the detection 
limit of conventional techniques (Figure 11).  Signals seen in the Western blots 
corresponded to unspecific bands as tested by incubating and developing the blot 
membranes with secondary antibody only. These non-specific bands are expected to be 
a consequence of blood components (data not shown).  
After PMCA, positive signal was detected in plasma (3/3 animals), brain (3/3 animals 
and intestines (1/3 animal) (Figure 12).  These results show that self-replicating prions 
can directly cross the intestinal barrier and target different organs.  The effective 
detection of PrPSc in brain and no other tissues is suspected to be a consequence of the 
PMCA conditions which has been standardized for this specific tissue.  As seen, all 
negative controls (substrate only) in the PMCA stayed negative s suggesting absence of 
false positive signals in our specimens (Figure 12). 
 
 
  
 
 
 
 
 
 
Figure 11. Western blot of 10% mouse tissue homogenates (before 
PMCA) taken two hours after per oral inoculation with sarkosyl 
treated PrPSc (RML) 
Colon, LI: Liver, SP: Spleen, BR: Brain
 
(A and B) ST: Stomach, IN: Intestines, CO: 
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Figure 12. Western blot of tissue homogenates after PMCA amplification
All samples are treated with PK 50µg/mL, 1h 37
electrophoresis. Three rounds done first round was five days followed by 48hrs round 
each. 50µL of 40% Tissue homogenate c
whole blood used (A).  Negative controls with just normal brain homogenate (
ST: Stomach, IN: Intestines, CO: Colon, LI: Liver, SP: Spleen, BR: Brain, PL: Plasma 
and BC: Buffy coat 
 
 
˚C at 600rpm before gel 
oncentrated. Blood equivalent to 400µL of 
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Summary 
Initial distribution of infectious material within hours of ingestion in vivo  
In this section, we were able to partially purify the prion protein from terminally 
infected mice brains, prepare the inoculum from it and successfully inoculate animals 
via oral ingestion.  Two hours after, animals were culled and various tissues, including 
blood, were collected and subjected to various rounds of PMCA.  Our results show the 
efficient detection of self- propagating prions in plasma for all three animals inoculated 
(Figure 12).  Also, positive signal was seen in intestines (1/3) and brain (3/3) animals. 
These results signify that within extremely short time after ingestion of prions the self- 
propagating agents can spread through the gastrointestinal barrier and be taken up by 
blood.  
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CHAPTER 4 
Discussion 
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4.1 Characterization of metabolic pattern of radioactively-labeled PrPSc  
The gastro-intestinal tract serves as an important barrier as well as interface for 
the materials orally ingested.  Much work has been done to study the transport of PrPSc 
from gut to brain (Kimberlin et.al. 1989; Beekes et.al. 2000; Andreoletti et al. 2000, 
Shmakov et.al.2001; Bergström et al. 2006; Kujala et al. 2011).  Surprisingly, very little 
is known about the metabolic profile of prions at short times after ingestion.  Most of 
the methods used previously to determine this were not sensitive enough to detect the 
smallest changes in the size distribution of the PrPSc aggregate after digestion.  
Knowing this information can be vital in determining the mechanism and initial fate of 
the infectious agent and its bioavailability in vivo.  In order to study PrPSc metabolism it 
is important to have a detailed and quantitative in vitro characterization of PrPSc 
stability in gastrointestinal tissue homogenates.  This information can provide data 
about the maximal capability of each tissue to metabolize PrPSc.  In this aim, we 
investigated PrPSc metabolism in various gastrointestinal tissues homogenates at 
different time points.  To achieve this, the first step was to have a pure and efficient 
preparation of PrPSc.  Various purification protocols have been reported that yield a 
variable degree of PrPSc purity.  In our studies we modified previous methods to obtain 
an extremely pure preparation of PrPSc from infected mouse brain homogenates (Figure 
3).  This is in agreement to a study that was just recently published showing purity of 
PrPSc  comparable to that obtained in our preparations (Wenborn et al. 2015).  Freshly 
prepared stomach, duodenum, jejunum, ileum and colon homogenates were separately 
incubated with biologically active radioactively labeled PrPSc.  Samples were collected 
at 1, 3 and 6 hours and analyzed by HPLC to determine the degradation profile of the 
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radiolabeled protein.  The difference in the profile of the radio-HPLC chromatogram of 
125I-PrPSc (input 125I-PrPSc) was compared to the profile after incubation with GI tract 
tissue homogenates.  Radiolysis and intactness was measured by TCA precipitation 
analysis coupled to HPLC characterization. Our results show for the first time that 
purified 125I-PrPSc incubated in duodenum, jejunum and ileum homogenates undergoes 
a significant degradation (more than 50%) which could be due to endogenous proteases 
present in the freshly prepared tissue homogenates.  This is in contrast to other tissue 
homogenates from the GI track, such as stomach and colon in which levels of 125I-PrPSc 
underwent minimal reduction.  It has been shown that the most probable site for PrPSc 
uptake after oral exposures are the intestinal lymphoid follicles (Payer’s patches) 
(Beekes & McBride, 2000).  Previous work has been done with gut loops from wild 
type sheep investigating the digestion of PrPSc in distal jejunum and ileum components 
at short time points ranging from 15 to 120min.  Their  results showed that PrPSc signal 
reduction is observed in both in vitro and in vivo intestinal environment (Dagleish et al. 
2010).  Studies done for 48 hours have shown almost complete degradation of 125I-PrPSc 
incubated in a cocktail of alimentary track fluids (Jeffrey et al. 2006).  However, these 
studies have just examined the digestion of PrPSc in distal jejunum and ileum and not in 
the duodenum and proximal jejunum. Also, these studies did not analyze a detailed 
profile of PrPSc degradation and unlike our highly sensitive experiments using 
radiolabeled PrPSc used less sensitive techniques like western blot for detection. Our 
results show that purified PrPSc appears as a broad peak with an estimated molecular 
weight of 310kDa, indicating of a small oligomer (8-10 monomers of PrP).  After 
incubation with duodenum and jejunum extracts (Figure 8) this oligomer is rapidly 
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degraded.  It has been shown previously that minimum infectious unit of PrPSc is a 
trimer of PrPSc (Groth, 1988), but the predominant species appear as large molecular 
weight fibrils and intermediate size oligomer in the range of what we observed in the 
present study.  It is likely that large fibrillar aggregates of PrPSc were removed during 
the purification or the radio-labeling procedure.  Nevertheless, it has been shown that 
the most infectious prion particles are oligomers of around 500KDa molecular weight 
(Silveira, 2005).  In the light of our finding it would be interesting to investigate further 
the exact role of duodenal and jejunum in uptake and transport of prions from GI tract 
to the brain in vivo. 
 
Detection of self-propagating prions in tissues after per-oral inoculation  
The most natural route for prion transmission is by ingestion of contaminated 
materials.  Previous results from our lab showed that prions intra-peritonealy injected in 
hamsters were detected in brains and spleens by PMCA within few days after 
inoculation, although at sub infectious levels (Chen et. al., 2014).  Here, we investigated 
the initial uptake of prions in blood at shorter time points after oral challenge which is 
probably the most natural route for transmission of prion diseases.  Much of the 
previous work has been done by infectivity bioassay to detect prions after long times 
after administration.  Moreover, most of the techniques used for detection in these 
studies were not sensitive enough to detect minute quantities of prions within hours in 
various tissues in vivo.  Here we showed that by employing the PMCA technology we 
can detect the tiny quantities of self-propagating prions in different biological samples 
after oral injection.  Three mice were inoculated with RML prions (an established 
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mouse prion strain) and sacrificed after 2 h.  The content of infectious prions in several 
organs related to prion uptake and transport were measured by PMCA (Figure 12).  
Positive signals for PrPSc were detected in plasma of all animals orally inoculated with 
prions. Previous work has shown that infectious agent can reach the brain from blood 
because of vascular deposition of PrPSc seen in the basement membrane of endothelial 
cells of hypothalamus (Sílvia Sisó, González, & Jeffrey, 2010).  Also, deposition of 
PrPSc in circumventricular organs in sheep was always observed regardless of the route 
of challenge suggesting that PrPSc can reach the brain by blood transport (S. Sisó, 
Jeffrey, & González, 2009).  In agreement with a recent study (Elder et al. 2015), our 
results show that prions orally ingested can cross the gastro-intestinal barrier and be 
taken up in blood within just two hours after inoculation.  Importantly, PrPSc found in 
blood and organs was intact and retained the capacity of self-propagating in a PMCA 
reaction (Figure 12).  Also, this is the first time self-propagating prions have been 
detected in brain after oral inoculation suggesting a direct transport of inoculated prions 
without peripheral replication.  This information can be vital in understanding the 
pathway followed by prions immediately after ingestion and quantifying the amount 
taken up by various tissues.  Also, work in this regard can help develop early 
interventional therapies and diagnostic tests for prion diseases.  
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Conclusions and future work 
In conclusion, as part of this work we have shown two findings that were not 
known previously in the field of prion diseases.  First, our metabolic profiles of prions 
in gastrointestinal tract show that duodenum, jejunum and ileum have the capacity to 
degrade PrPSc.  For future, it would be necessary to study this in an in vivo setting to 
map a distribution and degradation profile of orally ingested prions. Secondly, we have 
shown that following oral ingestion of prions the self-propagating agent reaches the 
blood and brain within just two hours.  Future work in this regard can involve a detailed 
quantitative study including more time points and tissues.  Also, it would be important 
to study the mechanisms responsible for PrPSc transport at the intestinal barrier and the 
subsequent distribution from blood to various tissues especially brain and what role 
does this play in the pathogenesis of the disease. 
The above study also lays some of the groundwork to obtain a detailed knowledge of 
how prions are taken up, distributed, metabolized and cleared from the body which can 
provide an estimation of tissue risks and development of therapeutic strategies. More 
than likely in natural infection of prions the quantity of the infectious agent an organism 
is exposed to is very low, thus it is imperative to know the quantity and mechanism of 
the amount of the infectious agent is absorbed, metabolized, distributed and cleared in 
the body. The initial fate of the infectious agent could play a vital role in determining 
how the disease would manifest and progress with time.  
The findings generated by bio-distribution and in vivo metabolite profiling can open 
novel avenues to develop therapeutic strategies aiming to prevent prions to get into the 
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brain or increasing prion elimination by enhancing metabolism.  Also, our finding that 
self-propagating prions can reach blood and brain within two hours of oral inoculation 
opens up new avenues to further investigate mechanistically how infectious prions can 
be taken up by various tissues leading to a catastrophic disease in the brain and what 
other alternate transport pathways play a role in facilitating disease pathogenesis.  
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